Agilent Technologies Inc. (Santa Clara, California, USA) has announced that it has completed its acquisition of cancer diagnostics company Dako (Glostrup, Denmark).
Agilent Technologies Inc. (Santa Clara, California, USA) has announced that it has completed its acquisition of cancer diagnostics company Dako (Glostrup, Denmark). Agilent expects the acquisition to help strengthen their position in life sciences, with a particular focus on product development to help in the fight against cancer.
Bill Sullivan, Agilent president and CEO, said, “The acquisition of Dako, the largest in Agilent's history, is another step in the expansion of our life science business. The addition of Dako and its portfolio will help Agilent accelerate our growth in several rapidly expanding areas of diagnostics, as well as strengthen our existing offerings. I look forward to the exciting possibilities ahead.”
Lars Holmkvist, Dako CEO, said, “Agilent and Dako have some of the best talent and technology in the world. By combining resources, we believe that both of our companies will benefit, as will our customers and employees. I have great confidence in what we will be able to accomplish together.”
For more information please visit ref="http://www.agilent.com">www.agilent.com
HPLC 2025 Preview: The Road To Sustainable Analytical Chemistry
May 20th 2025Elia Psillakis from the Technical University of Crete, Greece, and winner of this year’s Silver Jubilee Award from the Chromatographic Society, which will be presented at HPLC 2025, gives an update on current initiatives in green analytical chemistry.
Hydrophilic Interaction Chromatography (HILIC) and Direct Online Disruption of Lipid Nanoparticles
May 19th 2025Two proof-of-concept hydrophilic interaction chromatography HILIC) methods were developed in a joint study conducted by the University of Geneva (Switzerland), Sanofi, and the Waters Corporation—one for disrupting LNPs and retaining the mRNA, and another for detecting only unencapsulated mRNA to assess encapsulation efficiency. LCGC International spoke to Jonathan Maurer, first author of the paper that resulted from this study, about the methods and the efforts that led up to their development.